WHICH PNEUMOCOCCAL VACCINE SHOULD YOU BE ADMINISTERING?

MARGOT L. SAVOY, MD, MPH, FAAFP, FABC, CPE, CMQ, FAAPL
CHRISTIANA CARE HEALTH SYSTEM
DEPARTMENT OF FAMILY & COMMUNITY MEDICINE
ABOUT DR. SAVOY

• Medical Director & Faculty, Christiana Care Health System Department of Family & Community Medicine and Delaware Division of Child Rehabilitative Services

• Clinical Assistant Professor, Sidney Kimmel Medical College at Thomas Jefferson University

• Chair, American Academy of Family Physicians Subcommittee on Clinical Preventive Services

• AAFP Liaison to the Advisory Committee on Immunization Practices
Dr. Savoy does not have any relevant financial disclosures.
After attending this webinar, participants should be able to:

- Briefly explain the epidemiology of pneumococcal disease in adults
- Identify the available pneumonia vaccines available
- Choose the correct pneumonia vaccine for a particular adult patient
AN OPPORTUNITY TO INTERACT

▪ To participate in the polls:
  ▪ Text DRSAVOY to 22333
  ▪ There is no charge to participate unless your phone carrier charges your for text messages
The question will show up on the screen.
After you sign up, just text your response
The responses will show up on the screen
What is your favorite ice cream flavor?

A. 

B. 

Start the presentation to activate live content
If you see this message in presentation mode, install the add-in or get help at PollEv.com/app
STREPTOCOCCUS PNEUMONIAE (PNEUMOCOCCUS)

- Lancet-shaped, gram-positive, facultative anaerobic bacteria
- Over 90 known serotypes
  - 10 most common serotypes account for ~62% of invasive disease worldwide
- Common inhabitants of the respiratory tract
- May be isolated from the nasopharynx of 5-90% of healthy persons
  - Varies based on the population and setting
STREPTOCOCCUS PNEUMONIAE (PNEUMOCOCCUS) CONT.

- Capsular polysaccharides are the primary basis for the pathogenicity of the organism.
- Type-specific antibody to capsular polysaccharide is protective.
- These antibodies and complement interact to opsonize pneumococci, which facilitates phagocytosis and clearance of the organism.

http://www.microbiologybook.org/bowers/immune%20cells.htm
STREPTOCOCCUS PNEUMONIAE (PNEUMOCOCCUS) CONT.

- Louis Pasteur first isolated pneumococcus in 1881 from the saliva of a patient with rabies.
- Friedlander and Talamon first made the association between the pneumococcus and lobar pneumonia in 1883.
- Earliest vaccine development was in 1911, but delayed once antibiotics were identified.
- First pneumococcal vaccine was licensed in the United States in 1977.
- The first conjugate pneumococcal vaccine was licensed in 2000.
The most common clinical presentation of pneumococcal disease among adults includes:

- Pneumonia
- Meningitis
- Bacteremia
- Otitis media
PNEUMOCOCCAL PNEUMONIA

- The incubation period of pneumococcal pneumonia is short, about 1 to 3 days.

- Symptoms include:
  - Abrupt onset of fever
  - Chills or rigors
  - Pleuritic chest pain
  - Productive cough
  - Dyspnea, tachypnea, hypoxia
  - Tachycardia, malaise, weakness
PNEUMOCOCCAL PNEUMONIA CONT.

- Estimated 400,000 hospitalizations per year in the United States
- Up to 36% of adult community-acquired pneumonias
- Common bacterial complication of influenza
- Case-fatality rate 5%–7%, higher in elderly
- 25-30% of patients with pneumococcal pneumonia also experience pneumococcal bacteremia

- Other complications:
  - empyema (i.e., infection of the pleural space)
  - pericarditis (inflammation of the sac surrounding the heart)
  - endobronchial obstruction, withatelectasis and lung abscess formation
PNEUMOCOCCAL BACTEREMIA  
(WITHOUT PNA)

- More than 12,000 cases per year in the United States
- Case-fatality rate ~20%; up to 60% among the elderly
- Asplenic patients at largest risk for fulminant disease

PNEUMOCOCCAL MENINGITIS

- Cause over 50% of all cases of bacterial meningitis in the United States
- Estimated 3,000–6,000 cases per year in the United States
- Case-fatality rate 8% among children
- Case-fatality rate 22% among adults
- Neurologic sequelae common among survivors
CONDITIONS THAT INCREASE RISK FOR INVASIVE PNEUMOCOCCAL DISEASE

▪ Decreased immune function — including hematologic cancer and HIV infection
▪ Asplenia (functional or anatomic)
▪ Chronic heart, pulmonary (including asthma in adults), liver or renal disease
▪ Cigarette smoking (in adults)
▪ Cerebrospinal fluid (CSF) leak
▪ Cochlear implant
The highest mortality rate for invasive pneumococcal disease is in:

- children <2 years of age
- persons with compromised antibody responses
- adults 65 years and older
Incidence and mortality rates of invasive pneumococcal disease in the US (2010) per 100,000

# PNEUMONIA IN MISSOURI

<table>
<thead>
<tr>
<th>U.S. LEADING CAUSES OF DEATH, 2012</th>
<th>TOTAL DEATHS</th>
<th>DEATH RATE***</th>
<th>STATE RANK*</th>
<th>U.S. RATE**</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Heart Disease</td>
<td>13,742</td>
<td>193.4</td>
<td>10th</td>
<td>170.5</td>
</tr>
<tr>
<td>2. Cancer</td>
<td>12,919</td>
<td>182.3</td>
<td>11th</td>
<td>166.5</td>
</tr>
<tr>
<td>3. Chronic Lower Respiratory Diseases</td>
<td>3,650</td>
<td>51.7</td>
<td>11th (tie)</td>
<td>41.5</td>
</tr>
<tr>
<td>4. Stroke</td>
<td>2,989</td>
<td>42.2</td>
<td>13th</td>
<td>36.9</td>
</tr>
<tr>
<td>5. Accidents</td>
<td>3,002</td>
<td>47.8</td>
<td>13th</td>
<td>39.1</td>
</tr>
<tr>
<td>6. Alzheimer’s Disease</td>
<td>1,863</td>
<td>25.9</td>
<td>24th</td>
<td>23.8</td>
</tr>
<tr>
<td>7. Diabetes</td>
<td>1,377</td>
<td>19.6</td>
<td>30th (tie)</td>
<td>21.2</td>
</tr>
<tr>
<td>8. Influenza/Pneumonia</td>
<td>1,213</td>
<td>17.0</td>
<td>13th</td>
<td>14.4</td>
</tr>
<tr>
<td>9. Kidney Disease</td>
<td>1,259</td>
<td>17.8</td>
<td>9th</td>
<td>13.1</td>
</tr>
<tr>
<td>10. Suicide</td>
<td>914</td>
<td>14.9</td>
<td>18th</td>
<td>12.6</td>
</tr>
</tbody>
</table>

★ = people who should have gotten immunization too
US LICENSED PNEUMOCOCCAL VACCINES

- 14-valent polysaccharide vaccine licensed (PPSV23)
- 23-valent polysaccharide vaccine licensed (PCV7)
- 7-valent polysaccharide conjugate vaccine licensed (PCV7)
- 13-valent PCV licensed

Years:
- 1977: 14-valent polysaccharide vaccine licensed
- 1983: 23-valent polysaccharide vaccine licensed (PPSV23)
- 2000: 7-valent polysaccharide conjugate vaccine licensed (PCV7)
- 2010: 13-valent PCV licensed
ABOUT THE VACCINES

PNEUMOCOCCAL POLYSACCHARIDE VACCINE

- Composed of purified preparations of pneumococcal capsular polysaccharide
- PPSV23 contains polysaccharide antigen from 23 types of pneumococcal bacteria that cause 60-76% of invasive disease
- Available in the U.S. as Pneumovax 23 (Merck)
  - contains 25 mcg of each antigen per dose and contains 0.25% phenol as a preservative
  - single-dose vial or syringe, and in a 5-dose vial
  - given by injection and may be administered either intramuscularly or subcutaneously

PNEUMOCOCCAL CONJUGATE VACCINE

- Composed of purified capsular polysaccharide from 13 types of pneumococcus conjugated to nontoxic diphtheria toxin (CRM197)
- Available in the U.S. as Prevnar 13 (Wyeth/Pfizer)
  - contains approximately 2.2 μg of polysaccharide from each of 12 serotypes and approximately 4.4 μg of polysaccharide from serotype 6B; the total concentration of CRM197 is approximately 34 μg.
  - Contains 0.02% polysorbate 80 (P80), 0.125 mg of aluminum as aluminum phosphate (AlPO4) adjuvant, 5mL of succinate buffer, and no thimerosal preservative.
- Prevnar 13 is a suspension for intramuscular injection available in 0.5 mL single-dose prefilled syringes.
<table>
<thead>
<tr>
<th>Vaccines</th>
<th>Effectiveness</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pneumococcal Polysaccharide Vaccine</td>
<td>Not effective in children younger than 2 years</td>
</tr>
<tr>
<td></td>
<td>60%–70% against invasive disease</td>
</tr>
<tr>
<td></td>
<td>Less effective in preventing pneumococcal pneumonia</td>
</tr>
<tr>
<td>Pneumococcal Conjugate Vaccine</td>
<td>More than 90% effective against invasive disease caused by vaccine serotypes</td>
</tr>
<tr>
<td></td>
<td>in children</td>
</tr>
<tr>
<td></td>
<td>45% effective against vaccine-type non-bacteremic pneumococcal pneumonia in</td>
</tr>
<tr>
<td></td>
<td>adults older than 65</td>
</tr>
<tr>
<td></td>
<td>75% effective against vaccine-type invasive disease in adults older than 65</td>
</tr>
</tbody>
</table>

**PPSV23 = Widest range of coverage**

**PCV13 = Best immunogenicity**
GIVING ADULTS ≥65 YEARS PCV13, PREVENTS:

- Invasive Pneumococcal Disease
- Community Acquired Pneumonia
AND YET, UNDER 65% OF ADULTS ≥65 YRS HAVE EVER RECEIVED A PNEUMOCOCCAL VACCINE (LET ALONE BOTH)
RATES ARE WORSE FOR OUR MINORITY PATIENTS!

NOTES: Data are based on household interviews of a sample of the civilian noninstitutionalized population. The analyses exclude the 4.0% of adults aged 65 and over with unknown pneumococcal vaccination status. Advisory Committee on Immunization Practices recommendations regarding who should receive pneumococcal vaccination have changed over the years, and changes in coverage estimates may reflect changes in recommendations. Of particular note, beginning in September 2014, all adults aged 65 and over are recommended to receive both the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine.
RAISE YOUR HAND IF YOU ARE NOT PROTECTED...
SO, WHO NEEDS WHICH VACCINES?
MS. JOHNSON

- 65 y/o
- Here for a “check-up”
- No complaints
- Non-smoker
- PMH significant for obesity (BMI=32)
- Medications: none
- Immunization hx: She has never gotten a “pneumonia vaccine” but does get a flu shot every year
Which would you give Ms. Johnson today?

Pneumovax 23 (PPSV 23)
Prevnar 13 (PCV13)
Neither
ACIP RECOMMENDATION:

▪ Both PCV13 and PPSV23 should be routinely administered in series to all adults aged ≥65 years. (Category A)

▪ The two vaccines should not be coadministered, and the minimum acceptable interval between PCV13 and PPSV23 is 8 weeks. The recommended interval is ≥1 year. (https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6434a4.htm) If a dose of PPSV23 is inadvertently given earlier than the recommended interval, the dose need not be repeated.
MS. JOHNSON

- She is 65 y/o and vaccine naive.
- She should get a Prevnar 13 today.

Abbreviations: PCV13 = 13-valent pneumococcal conjugate vaccine
PPSV23 = 23-valent pneumococcal polysaccharide vaccine.
*Minimum interval between sequential administration of PCV13 and PPSV23 is 8 weeks. PPSV23 can be given later than 6–12 months after PCV13 if this window is missed.
MS. SMITH

- 68 y/o
- Here for her Medicare annual wellness visit
- Smokes 1 ppd for 50 years
- PMH significant for COPD, HTN
- Medications: inhalers, HCTZ/metoprolol
- Immunization hx: Was given Pneumovax 23 at 65 y/o, gets influenza vaccine every year
Does Mrs. Smith need a pneumonia vaccine today?
MS. SMITH

- She is 68 y/o and got PPSV23 at 65 y/o.
- It is over 1 year since PPSV23 so she should get PCV 13 today.

Abbreviations: PCV13 - 13-valent pneumococcal conjugate vaccine; PPSV23 - 23-valent pneumococcal polysaccharide vaccine.
*Minimum interval between sequential administration of PCV13 and PPSV23 is 8 weeks. PPSV23 can be given later than 6-12 months after PCV13 if this window is missed.
MR. JONES

- 46 y/o
- Here for diabetes follow-up
- Non-smoker
- PMH significant for DM, ty1
- Medications: insulin, statin, ace-inh
- Immunization hx: gets influenza vaccine every year, has never had any “pneumonia” vaccine
Which vaccine should Mr. Jones get today?

None

Prevnar 13 (PCV13)

Pneumovax 23 (PPSV23)
- Adults aged 19 through 64 years with chronic heart disease including congestive heart failure and cardiomyopathies (excluding hypertension); chronic lung disease including chronic obstructive lung disease, emphysema, and asthma; chronic liver disease including cirrhosis; alcoholism; or diabetes mellitus; or who smoke cigarettes should receive PPSV23.

- At age 65 years or older, they should receive PCV13 and another dose of PPSV23 at least 1 year after PCV13 and at least 5 years after the most recent dose of PPSV23.
MR. JONES

- He has diabetes but no other immunosuppressing illnesses.
- He should get Pneumovax 23 (PPSV23) today.
When Mr. Jones turns 65, which vaccine should he get?

Prevnar 13 (PCV13)
Pneumovax 23 (PPSV 23)
Neither (he is up to date)
▪ Adults aged 19 through 64 years with chronic heart disease including congestive heart failure and cardiomyopathies (excluding hypertension); chronic lung disease including chronic obstructive lung disease, emphysema, and asthma; chronic liver disease including cirrhosis; alcoholism; or diabetes mellitus; or who smoke cigarettes should receive PPSV23.

▪ At age 65 years or older, they should receive PCV13 and another dose of PPSV23 at least 1 year after PCV13 and at least 5 years after the most recent dose of PPSV23.
MR. PHILLIPS

- 32 y/o
- Here for follow-up
- Non-smoker
- PMH significant for sickle cell disease, has spleen removed at 22
- Medications: folic acid
- Immunization hx: gets influenza vaccine every year, “got 2 pneumonia shots” after his surgery
What immunization should Mr Phillips receive today?

PPSV23

PCV13

None, he is up to date.
- Adults aged 19 years or older with immunocompromising conditions or *anatomical or functional asplenia* (described below) should receive **PCV13 and a dose of PPSV23** at least 8 weeks after PCV13, followed by a second dose of PPSV23 at least 5 years after the first dose of PPSV23.

- If the most recent dose of PPSV23 was administered before age 65 years, at age 65 years or older, administer another dose of PPSV23 at least 8 weeks after PCV13 and at least 5 years after the most recent dose of PPSV23.
MR. PHILLIPS

- Has asplenia
- Sounds like he was given the PCV and PPSV23 after his surgery BUT he didn’t get the PPSV23 booster at 27 years old (5 years later)

  - **Give PPSV 23 today**
What immunization(s) does Mr. Phillips need once he gets to 65?

None - he is all done!

Just a PPSV23

A PCV13 at 65

Start the presentation to activate live content
If you see this message in presentation mode, install the add-in or get help at PollEv.com/app
Adults aged 19 years or older with immunocompromising conditions or anatomical or functional asplenia (described below) should receive PCV13 and a dose of PPSV23 at least 8 weeks after PCV13, followed by a second dose of PPSV23 at least 5 years after the first dose of PPSV23.

If the most recent dose of PPSV23 was administered before age 65 years, at age 65 years or older, administer another dose of PPSV23 at least 8 weeks after PCV13 and at least 5 years after the most recent dose of PPSV23.
MR. PHILLIPS

- Has asplenia
- Was given the PCV and PPSV23 after his surgery and the PPSV23 booster
- **So needs PPSV23 only at age 65**
MR. PHILLIPS

- Oh, by the way... My parents are turning 65 this year and I wanted to get them their flu shot on the same day as the pneumonia one, but I read on Facebook that you can’t get both on the same day, is that true?
the Philips parents get PCV13 and Influenza vaccine at the same visit.
YES, YOU CAN GIVE BOTH ON THE SAME DAY

▪ Concomitant administration of PCV13 and trivalent inactivated influenza vaccine (TIV) has been demonstrated to be immunogenic and safe.

▪ PCV13 can be co-administered with TIV in an adult immunization program.

▪ However, a randomized double-blind trial found slightly lower pneumococcal serotype–specific geometric mean concentrations and lower proportion achieving at least a fourfold rise in hemagglutination inhibition assay titer for one of three influenza subtypes (influenza A[H3N2]) with PCV13 plus TIV compared with PCV13 alone or TIV alone among adults aged ≥65 years.
  ▪ One of the 3 didn’t make as much antibody as the others when given on the same day, but it was a small effect and not enough to change the recommendation

▪ Currently, no data are available on co-administration with other vaccines (e.g., tetanus, diphtheria, and acellular pertussis vaccine or zoster vaccine) among adults.
WHAT ABOUT ZOSTER VACCINE?

▪ PPSV23
  ▪ Merck package insert: In a randomized clinical study, a reduced immune response to Zostavax as measured by gpELISA was observed in individuals who received concurrent administration of Pneumovax 23 and Zostavax compared with individuals who received these vaccines 4 weeks apart.
    ▪ Consider administration of the two vaccines separated by at least 4 weeks.

▪ PCV13
  ▪ There is no data about giving PCV13 and Zostavax on the same day.

http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm200862.htm
WHAT ABOUT ZOSTER VACCINE?

“In December 2009 Merck revised the package insert for herpes zoster vaccine (HZV) to advise that HZV and 23-valent pneumococcal polysaccharide vaccine (PPSV) should not be administered concurrently. This recommendation was based on a Merck study that showed the average titer against varicella zoster virus (VZV) was lower in persons who received zoster and PPSV at the same visit compared to persons who received these vaccines 4 weeks apart. However, the clinical relevance of this observation is unknown because there is no evidence to indicate that antibody titers against VZV are a measure of protection against HZ (results were additionally confounded by unexplained differences across comparison group in the baseline VZV antibody titers). Antibody levels to PPSV serotypes 3, 14, 19A, and 22F were assessed during this study and were unaffected by simultaneous administration, though significance of this observation is also unknown. Finally, the safety profile of HZV is unaffected by simultaneous administration of PPSV. Consequently, to avoid introducing barriers to patients and providers who are interested in these two important vaccines, CDC has not changed its recommendation for either vaccine, and continues to recommend that HZV and PPSV be administered at the same visit if the person is eligible for both vaccines.”
TAKE HOME POINTS

- Adults ≥ 65 years old need PCV13 AND PPSV23.
- Give PCV 13 first if vaccine naive and then give PPSV 23 1 year later.
- Adults 19-64 years with immunosuppression, asplenia or other chronic medical conditions may need PCV13 and/or PPSV23.
  - Often the answer is yes to PPSV23
  - Sometimes the answer is no to PCV13
  - Don’t try to guess– check the ACIP schedule!
Figure 2. Recommended immunization schedule for adults aged 19 years or older by medical condition and other indications, United States, 2017

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Pregnancy</th>
<th>Immunocompromised (excluding HIV infection)</th>
<th>HIV infection CD4+ count (cells/µL)</th>
<th>Asplenia, persistent complement deficiencies</th>
<th>Kidney failure, end-stage renal disease, on hemodialysis</th>
<th>Heart or lung disease, chronic alcoholism</th>
<th>Chronic liver disease</th>
<th>Diabetes</th>
<th>Healthcare personnel</th>
<th>Men who have sex with men</th>
</tr>
</thead>
<tbody>
<tr>
<td>PCV13</td>
<td></td>
<td></td>
<td>&lt; 200</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PPSV23</td>
<td></td>
<td></td>
<td>≥ 200</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1 dose

1, 2, or 3 doses depending on indication

Recommended for adults who meet the age requirement, lack documentation of vaccination, or lack evidence of past infection

Recommended for adults with additional medical conditions or other indications

Contraindicated

No recommendation


*PORTIONS OF TABLE EXCLUDED FOR CLARITY
### Adult Pneumococcal Vaccination Table

The Advisory Committee on Immunization Practices (ACIP) recommends all adults 65 years of age and older receive both PCV13 and PPSV23 pneumococcal vaccinations. ACIP also recommends adults 19 through 64 years of age who have underlying medical conditions receive pneumococcal vaccination with PCV13, PPSV23, or both. A second dose of PPSV23 before age 65 is not recommended for adults with Central Spinal Fluid Leaks or adults with cochlear implants.

<table>
<thead>
<tr>
<th>RISK GROUP</th>
<th>UNDERLYING MEDICAL CONDITION</th>
<th>PCV13 RECOMMENDED</th>
<th>PCV13 RECOMMENDED</th>
<th>REVACCINATION AT 5 YEARS AFTER FIRST DOSE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immunocompetent persons</td>
<td>Chronic heart disease; congestive heart failure and cardiomyopathies</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chronic lung disease: chronic obstructive lung disease, emphysema, and asthma</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Diabetes mellitus</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Central Spinal Fluid Leaks</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cochlear implants</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Alcoholism</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chronic liver disease</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chronic renal disease</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cerebrospinal fluid clots</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Persons with functional or acquired immunodeficiency</td>
<td>Autoimmune disorders/immunodeficiencies: includes both humoral or T lymphocyte deficiency; complement deficiencies; IgA, IgG, IgM deficiencies; and hypogammaglobulinemia, including chronic granulomatous disease</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>HIV infection</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chronic renal failure</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hemolytic anemia</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Leukemia</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lymphoma</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Neutropenia</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Generalized malignancy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Leukemia and immunosuppression: diseases requiring treatment with immunosuppressive drugs, long-term systemic corticosteroids, and radiation therapy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Solid organ transplant</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Multiple myeloma</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

**Adult Pneumococcal Vaccination Table Diagram**

- **Has person had a PCV13 vaccination before?**
  - **YES**: No further PCV13 doses needed. Administer PPSV23 12 months after PCV13.
  - **NO**: Was PPSV23 administered before patient was 65 years of age?
    - **YES**: Administer PCV13 at least once after PPSV23. When person is 65 years of age repeat PPSV23 vaccination spacing the PPSV23 doses a minimum of five years apart.
    - **NO**: Administer PPSV23 12 months later.
- **Is person 65 years of age or older?**
  - **YES**: Administer PCV13 at least once after PPSV23.
  - **NO**: Administer PPSV23 12 months after if person meets ACIP guidelines boost PPSV23 vaccine five years after first dose. When person is 65 years of age repeat dose of PPSV23 spacing the PPSV23 doses a minimum of five years apart.

---


---

**You never outgrow the need for vaccines.**
Shop IAC: Laminated Schedules

Laminated child & teen and adult CDC Immunization Schedules are ready for heavy duty use.

Laminated Adult Immunization Schedule

OUT OF STOCK. Please check back in March 2017 for the updated adult schedule.

Product Number: R2009
Date Published: 2016
Description:
Need durable copies of the recommended adult immunization schedules to put in every patient exam room? Well, IAC has them! IAC's copies of the ACIP/APPAC/ACGG/ACIP - approved schedule for adults are laminated for heavy-duty use, complete with essential footnotes, and printed in color for easy reading.

In addition, IAC has included a list of contraindications and precautions that should be considered before vaccines are administered. The list is shown in Table 1, “Guide to Contraindications and Precautions to Commonly Used Vaccines in Adults,” which is adapted from “General Recommendations on Immunizations: Recommendations of the Advisory Committee on Immunization Practices.”

Dimensions:
Eight pages printed back-to-back, folded to 8.5” x 11”

Pricing:
1-4 copies $7.50 each
5-19 copies $5.50 each
20-99 copies $4.50 each
100-499 copies $4.00 each
500-999 copies $3.50 each

Note: For quotes on larger quantities or customizing call 851-847-0009 or email admininfo@immunize.org

Credits:
Created and distributed by the Immunization Action Coalition.

http://www.immunize.org/shop/laminated-schedules.asp
ANY QUESTIONS?